<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="53731">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01975831</url>
  </required_header>
  <id_info>
    <org_study_id>LUD2013-003</org_study_id>
    <nct_id>NCT01975831</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab</brief_title>
  <official_title>A Phase 1 Study to Evaluate the Safety and Tolerability of Anti-PD-L1, MEDI4736, in Combination With Tremelimumab in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig Institute for Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Research Institute, New York City</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ludwig Institute for Cancer Research</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open-label,  study with a standard 3+3 dose-escalation phase,
      followed by an expansion phase in subjects with solid tumors
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>Up to 1 year</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration time curve, maximum concentration, clearance, half-life after administration of MEDI4736 and Tremelimumab</measure>
    <time_frame>Up to 15 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of subjects who develop detectable anti-drug antibodies (ADAs)</measure>
    <time_frame>Up to 15 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Response by the Immune-related Response Criteria</measure>
    <time_frame>Up to 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Response using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors</measure>
    <time_frame>Up to 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>Up to 5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>MEDI4736 &amp; Tremelimumab Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI4736 and Tremelimumab will be administered by IV infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI4736</intervention_name>
    <arm_group_label>MEDI4736 &amp; Tremelimumab Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tremelimumab</intervention_name>
    <arm_group_label>MEDI4736 &amp; Tremelimumab Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically- or cytologically-confirmed solid tumor with at least one measurable
             lesion.

          -  Failed to respond to or relapsed following standard treatment, or declined or was not
             eligible for standard treatment.

          -  ECOG performance status of 0-2.

          -  Anticipated lifespan greater than 6 month.

          -  Adequate organ and marrow function

          -  Able and willing to give valid written informed consent.

          -  Able and willing to give valid written consent for archival tumor samples

          -  Able and willing to give valid written consent for biopsy samples (subjects in the
             expansion phase only).

        Exclusion Criteria:

          -  Prior exposure to Tremelimumab or MEDI4736 or other anti-CTLA-4, anti-PD-1,
             anti-PD-L1 antibodies

          -  History of severe allergic reactions to any unknown allergens.

          -  Active or prior autoimmune disease except for autoimmune thyroiditis or vitiligo.

          -  Any prior Grade â‰¥ 3 immune-related adverse event (irAE) or any prior
             corticosteroid-refractory irAE.

          -  Known active or chronic viral hepatitis or history of any type of hepatitis within
             the last 6 months.

          -  History of sarcoidosis syndrome.

          -  Active or history of inflammatory bowel disease (colitis, Crohn's), diverticulitis,
             irritable bowel disease, celiac disease, or other serious, chronic, gastrointestinal
             conditions associated with diarrhea. Active or history of systemic lupus
             erythematosus or Wegener's granulomatosis.

          -  Metastatic disease to the central nervous system for which other therapeutic options,
             including radiotherapy, may be available.

          -  Known immunodeficiency or active HIV.

          -  Participation in any other clinical trial involving another investigational agent
             within 4 weeks prior to day 1 of the study.

          -  Mental impairment that may compromise the ability to give informed consent and comply
             with the requirements of the study.

          -  Women who are breast feeding or pregnant

          -  Women of childbearing potential not using a medically acceptable means of
             contraception for the duration of the study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jedd Wolchok, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>MSKCC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephane Bertolini, PharmD</last_name>
    <phone>2124501587</phone>
    <email>sbertolini@licr.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 25, 2014</lastchanged_date>
  <firstreceived_date>October 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
